Due to the efficacy of improving immunosuppressive microenvironment, anti-PD-1/PD-L1 treatment is suggested to be a promising therapeutic method for recurrent or metastatic NPC patients. The gene discussed is CD274; the disease is nasopharyngeal carcinoma.